BioSpace News Archive

G1 Therapeutics, Inc., a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m. ET.

Palisade Bio, Inc. announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.

Simulations Plus, Inc. announced an extension to the formal agreement with the Translational Toxicology Division at the National Institute of Environmental Health Sciences to support the rapid safety assessment of chemicals in animals and humans.

Pacira BioSciences, Inc. announced the publication of its pivotal Phase 3 study supporting the efficacy and safety of EXPAREL® as a single-dose sciatic nerve block in the popliteal fossa in patients undergoing bunionectomy.

Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company, announced the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.

The Muscular Dystrophy Association announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific Conference, where she will address the world’s leaders in neuromuscular disease research and care.

Amylyx Pharmaceuticals, Inc. announced that two abstracts detailing next steps in the development of the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of amyotrophic lateral sclerosis and findings from a pharmacokinetic and pharmacodynamic study of AMX0035 in people with ALS will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference on March 3-6, 2024 in Orlando, Florida.

Adial Pharmaceuticals, Inc. announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024.

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three and twelve months ended December 31, 2023.

Provectus Biopharmaceuticals, Inc. announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates.